Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CMB
vs
S
S&P/ASX 300
CMB
Over the past 12 months, CMB has outperformed S&P/ASX 300, delivering a return of +10% compared to S&P/ASX 300's 4% drop.
Stocks Performance
CMB vs S&P/ASX 300
Performance Gap
CMB vs S&P/ASX 300
Performance By Year
CMB vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cambium Bio Ltd
Glance View
Cambium Bio Ltd. engages in the development and commercialization of regenerative therapies derived from novel processed human platelets. The firm's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The Company’s lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. The company contains enriched levels of regenerative factors, protease inhibitors, minerals and vitamins. In addition, the Company's stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. The company is also developing Sygenus, a preclinical secretome-based biologic for wound healing.
